Načítá se...
Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial
AIM: To examine the efficacy and safety of otilonium bromide (OB) in treatment-sensitive functional irritable bowel syndrome (IBS) clinical parameters. METHODS: Ninety-three patients (44.8 ± 12.6 years, 69% female) with IBS symptoms complying with Rome II criteria participated in this double-blind,...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4161814/ https://ncbi.nlm.nih.gov/pubmed/25232263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i34.12283 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|